- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01978327
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
June 7, 2017 updated by: GlaxoSmithKline
Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2647544 and Its Potential Pharmacokinetic Interaction With Simvastatin in Healthy Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
The current study is a single-blind, randomised, placebo-controlled, 4-cohort study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat doses of GSK2647544.
Cohorts 1, 2 and 3 will evaluate escalating doses of GSK2647544 in young healthy volunteers for 7 days, 7 days, and 14 days, respectively.
Cohort 4 will evaluate repeat doses of GSK2647544 in healthy elderly volunteers for 14 days.
Additionally, Cohorts 1 and 3 will include an assessment of potential drug-drug interaction with simvastatin to examine CYP3A4 inhibition by GSK2647544.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Middlesex
-
Harrow, Middlesex, United Kingdom, HA1 3UJ
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females who are 18 to 64 years of age inclusive, defined as young subjects in this study, are eligible for Cohorts 1-3 only
- Males and females who are ≥65 years of age, defined as elderly subjects in this study, are eligible for Cohort 4 only
- Healthy as determined by a responsible and experienced physician
- A female subject is eligible to participate if she is of non-childbearing potential
- Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods
- Body weight > 50 kg (110 pounds) and body mass index (BMI) between 19 and 32
- Aspartate aminotransferase (AST), Alanine transaminase (ALT), alkaline phosphatase and bilirubin <= 1.5xUpper Limit of Normal (ULN)
- Average of triplicate QTcB values and average of triplicate QTcF values must both < 450 msec
- Capable of giving written informed consent
Exclusion Criteria:
- Subjects with Lp-PLA2 activity <=20 nanomole/minute/milliliter (mL)(for subjects with 2 known birth parents of at least 50% Japanese, Chinese, or Korean ancestry)
- History of asthma, anaphylaxis or anaphalactoid reactions, severe allergic responses
- History of hypercoagulable state or history of thrombosis
- History of biliary tract disease including a history of liver disease with elevated liver function tests of known or unknown etiology
- Positive Human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C at screening
- History of regular use of tobacco or nicotine-containing products within 6 months of the study
- Unable to abstain from alcohol or caffeine or xanthine-containing products for 24 h prior to the start of dosing
- Unable to refrain from use of prescription or non-prescription drugs and vitamins within 7 days or 5 half-lives (whichever is longer) prior to administration of study
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening (Note: This applies to healthy young subjects screened for Cohorts 1-3 only. Healthy elderly subjects for cohort 4 who are social smokers must give up smoking for the period that they will be on the unit)
- positive pre-study drug/alcohol screen
- Unable to refrain from consumption of Seville oranges, grapefruit or grapefruit juice within 7 days prior to the first dose of study medication until the follow-up visit
- Subjects who have taken statins, medicines that are contraindications of statins, know potent inhibitiors or inducers of CYP3A4 in the 4 weeks or 5 half-lives (whichever is longer) prior to screening and are not able to discontinue use throughout participation in the clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Matching placebo
|
repeat dose
|
Experimental: GSK2647544
The planned repeat doses of GSK2647544 are 80 mg bid, 200 mg bid, and 350 mg bid
|
repeat dose
|
Experimental: simvastatin
for drug-drug interaction
|
drug-drug interaction
|
Experimental: simvastatin co-dosed with GSK2647544
for drug-drug interaction
|
drug-drug interaction
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of GSK2647544 as assessed by number of subjects with adverse events (AE)s
Time Frame: up to 19 days in each dosing session
|
Safety and tolerability parameters will include recording of AEs
|
up to 19 days in each dosing session
|
Safety and tolerability of GSK2647544 as assessed by change from Baseline in laboratory values
Time Frame: up to 15 days in each dosing session
|
Safety and tolerability parameters will include laboratory (haematology, clinical chemistry, urinalysis) values at Screening, Day-1, Day 1 to up to Day 15 and Follow-up (7-14 days post-last dose)
|
up to 15 days in each dosing session
|
Safety and tolerability of GSK2647544 as assessed by change from Baseline in ECG readings
Time Frame: up to 19 days in each dosing session
|
Safety and tolerability parameter will include the electrocardiogram (ECG) readings at Screening, Day -1, Day 1 to up to Day 19, and follow-up (7-14 days post-last dose)
|
up to 19 days in each dosing session
|
Safety and tolerability of GSK2647544 as assessed by change from Baseline in Telemetry ECG parameters
Time Frame: 2 days in Cohorts 1, 2 and 4; 3 days in Cohort 4
|
Safety and tolerability parameter will include the Telemetry ECG readings from 30 minutes pre-dosing till 24 hours post-dosing
|
2 days in Cohorts 1, 2 and 4; 3 days in Cohort 4
|
Safety and tolerability of GSK2647544 as assessed by change from Baseline in vital signs
Time Frame: up to 19 days in each dosing session
|
Vital signs measurement include systolic and diastolic blood pressure and pulse rate at Screening, Day -1, Day 1 to up to Day 19, and Follow-up (7-14 days post-last dose)
|
up to 19 days in each dosing session
|
Safety and tolerability of GSK2647544 as assessed by Columbia Suicide Severity Rating Scale (C-SSRS)
Time Frame: 4 days in Cohorts 1 and 2; 8 days in Cohorts 3 and 4
|
C-SSRS will be measured at Screening, Day-1, dispersed days during dosing sessions, prior to discharge, and Follow-up (7-14 days post-last dose)
|
4 days in Cohorts 1 and 2; 8 days in Cohorts 3 and 4
|
Peak plasma concentration (Cmax) of GSK2647544
Time Frame: up to 17 days in GSK2647544 dosing sessions
|
To assess PK profile of GSK2647544, Cmax of GSK2647544 will be measured
|
up to 17 days in GSK2647544 dosing sessions
|
Time of peak plasma concentration (tmax) of GSK2647544
Time Frame: up to 17 days in GSK2647544 dosing sessions
|
To assess PK profile of GSK2647544, tmax of GSK2647544 will be measured
|
up to 17 days in GSK2647544 dosing sessions
|
Area under the time concentration curve (AUC) of GSK2647544
Time Frame: up to 17 days in GSK2647544 dosing sessions
|
To assess PK profile of GSK2647544, AUC of GSK2647544 will be measured
|
up to 17 days in GSK2647544 dosing sessions
|
Terminal half-life (t½ ) of GSK2647544
Time Frame: up to 17 days in GSK2647544 dosing sessions
|
To assess PK profile of GSK2647544, t1/2 of GSK2647544 will be measured
|
up to 17 days in GSK2647544 dosing sessions
|
Time of peak plasma concentration (tmax) of simvastatin
Time Frame: 4 days in Cohorts 1 and 3
|
To assess the effect of GSK2647544 on PK profile of simvastatin, tmax of simvastatin will be measured
|
4 days in Cohorts 1 and 3
|
Area under the time concentration curve (AUC) of simvastatin
Time Frame: 4 days in Cohorts 1 and 3
|
To assess the effect of GSK2647544 on PK profile of simvastatin, AUC of simvastatin will be measured
|
4 days in Cohorts 1 and 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predose plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and postdose Lp-PLA2 activity
Time Frame: up to 18 days in GSK2647544 dosing sessions
|
Lp-PLA2 activity will be measured at Days 1, 2, 3 and 4 in GSK2647544 single dose sessions; it will be measured at Days 1, 3, 4, 5, 7, 10, 14, 15, 16, 17 and 18 in GSK2647544 repeat dose sessions
|
up to 18 days in GSK2647544 dosing sessions
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 22, 2013
Primary Completion (Actual)
March 3, 2014
Study Completion (Actual)
March 3, 2014
Study Registration Dates
First Submitted
October 31, 2013
First Submitted That Met QC Criteria
October 31, 2013
First Posted (Estimate)
November 7, 2013
Study Record Updates
Last Update Posted (Actual)
June 8, 2017
Last Update Submitted That Met QC Criteria
June 7, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200592
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Dataset Specification
Information identifier: 200592Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 200592Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 200592Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 200592Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 200592Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 200592Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 200592Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on GSK2647544
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineTerminated